Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity | Markets Insider
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the Mark...
WS Investor
2025-01-18
Comments
Share your comments